Group 1: Clinical Trial Results - The Phase 1 study results for RLYB116 demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, with a safety profile consistent with other subcutaneous biologics [2] - RLYB116 showed promising pharmacokinetic and pharmacodynamic results, indicating clinically effective blockade of terminal complement [2] - RLYB116 administered at 150 mg and 300 mg once a week was well tolerated, with no gastrointestinal side effects reported among participants [3] Group 2: Future Plans - Rallybio plans to initiate a Phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with topline data expected in 2027 [4] Group 3: Technical Analysis - Rallybio is currently trading 4.5% below its 20-day simple moving average (SMA) and 8.2% below its 100-day SMA, indicating bearish momentum in the short to medium term [5] - Shares have decreased 17.97% over the past 12 months and are positioned closer to their 52-week lows than highs [5] - The combination of neutral RSI and bearish MACD indicates mixed momentum for Rallybio, reflecting uncertainty in the stock's near-term direction [6] Group 4: Sector Performance - Rallybio is part of the healthcare sector, which is currently ranked 5 out of 11 sectors, reflecting mid-tier performance [7] - The healthcare sector has seen a modest increase of 1.46% over the past 30 days and a rise of 3.51% over the last 90 days, highlighting that Rallybio's recent performance has not mirrored this trend [7] Group 5: Market Position - According to Benzinga Edge, Rallybio's momentum is weak, with a score of 17.09, indicating underperformance compared to the broader market [8] - Rallybio shares were down 6.64% at $4.50 at the time of publication [8] - Key resistance for the stock is at $5.50, while key support is at $4.50 [9]

2 Transforming innovation into durable value creation Apellis: The Leading Complement Company 44th Annual J.P. Morgan Healthcare Conference Cedric Francois, M.D., Ph.D. Co-Founder, Chief Executive Officer and President January 12, 2026 ARCHER Living with C3G Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of ...

Core Viewpoint - Annexon, Inc. has initiated a public offering of $75 million in common stock or pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more, aimed at advancing its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Company Overview - Annexon, Inc. is focused on developing next-generation complement inhibitors to address neuroinflammation, targeting diseases affecting the body, brain, and eye [5]. - The company’s approach centers on C1q, a key molecule in the inflammatory pathway, with the goal of preventing tissue damage in various diseases [5]. - Annexon’s pipeline includes investigational drug candidates across three therapeutic areas: autoimmunity, neurodegeneration, and ophthalmology, addressing the needs of nearly 10 million people globally [5]. Offering Details - The public offering is being conducted under a shelf registration statement filed with the SEC, with a preliminary prospectus supplement to be made available [3]. - Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are serving as joint book-running managers for the offering [2].

Core Points - Omeros Corporation will announce its financial results for Q3 2025 on November 13, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments [1] Company Overview - Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for complement-mediated diseases, cancers, and addictive disorders [5] - The lead product, narsoplimab, is under regulatory review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [5] - OMS1029, a long-acting MASP-2 inhibitor, has completed Phase 1 clinical trials, while zaltenibart (OMS906) is in development for PNH and C3 glomerulopathy [5] - Novo Nordisk has acquired global rights to zaltenibart, including associated intellectual property [5] - Omeros' pipeline includes OMS527, a phosphodiesterase 7 inhibitor for cocaine use disorder, funded by the National Institute on Drug Abuse [5]